<DOC>
	<DOCNO>NCT00208546</DOCNO>
	<brief_summary>This study ass efficacy safety addition cetuximab combine regimen capecitabine , oxaliplatin bevacizumab patient previously untreated advanced colorectal carcinoma . It open , comparative study , compare effect capecitabine , oxaliplatin bevacizumab regimen plus cetuximab . Seven hundred fifty patient include . Treatment continue disease progression serious toxicity follow continue death . It anticipate addition cetuximab lead increase progression free survival .</brief_summary>
	<brief_title>Cetuximab , Capecitabine , Oxaliplatin Bevacizumab Advanced Colorectal Cancer</brief_title>
	<detailed_description>Primary objective : To assess efficacy , define progression-free survival ( PFS ) , add cetuximab capecitabine/oxaliplatin/bevacizumab advance CRC . Secondary objective : To assess tumour response ( CR , PR SD ) , response duration , overall survival , toxicity profile , quality life , translational research . Methodology : Open , randomised multicenter phase III study . The number patient 750 . Test product : All cycle administer q 3 week . Oxaliplatin discontinue 6 cycle study arm . The dose capecitabine increase 1250 mg/m2 b.i.d . cycle 7 . Arm A : capecitabine 1000 mg/m2 orally b.i.d . day 1-14 ( 1250 mg/m2 6 cycle ) , oxaliplatin 130 mg/m2 i.v . infusion day 1 6 cycle , bevacizumab 7.5 mg/kg i.v . infusion day 1 . Arm B : capecitabine 1000 mg/m2 orally b.i.d . day 1-14 ( 1250 mg/m2 6 cycle ) , oxaliplatin 130 mg/m2 i.v . infusion day 1 6 cycle , bevacizumab 7.5 mg/kg i.v . infusion day 1 . Cetuximab 400 mg/m2 i.v . day 1 cycle 1 , thereafter weekly 250 mg/m2 i.v . Duration treatment follow-up : Treatment continue disease progression , unacceptable toxicity . Patients evaluate every 9 week response treatment , time point progression suspect . After cessation therapy reason disease progression , patient follow every 3 month progression death . Death and/or progression report whenever occurs . In case chemotherapy ( i.e . capecitabine and/or oxaliplatin ) discontinue reason toxicity , treatment bevacizumab ( arm A ) bevacizumab + cetuximab ( Arm B ) continue progression unacceptable toxicity . Also , chemotherapy plus bevacizumab discontinue Arm B reason toxicity , treatment cetuximab continue progression unacceptable toxicity . Criteria evaluation : Efficacy : All eligible patient include analysis ( intent-to-treat ) . All patient receive &gt; 9 week treatment ( i.e . 3 cycle ) consider evaluable response , unless document progression occur earlier . Safety profile : Safety analyse treatment group . Patients receive â‰¥ 1 treatment dos evaluable toxicity . Evaluation perform safety population ( receive treatment , assignment treatment group treat ) . Clinical laboratory toxicity/symptomatology grade accord NCI common toxicity criterion , version 3.0 . The adverse event report NCI common toxicity criterion grade : mild , moderate , severe , life threatening . Statistical methodology : The main endpoint study progression free survival interval ( PFS ) . PFS curve construct mean Kaplan Meier method . Comparisons PFS curve perform mean log rank test . Similar method use analyse duration survival . All analyse do accord intention-to-treat principle . The expected median PFS Arm A ( standard arm ) 11 month . The minimum increase PFS Arm B ( experimental arm ) 3 month ( 21 % hazard ratio reduction ) . 540 event require 80 % power . 740 patient need show difference ( &gt; =0.05 , 2-tailed test ) . To allow ineligibility patient , total 750 patient include . Stratification parameter : Patients stratify follow parameter : - Prior adjuvant therapy ( yes versus ) ; - Number organ affect ( 1 versus &gt; 1 , case primary tumour situ count one organ ) ; - Serum LDH ( normal versus normal ) ; - Per participate institution . Side study : Side study prognostic factor tumour sample include patient perform , well circulate tumour cell endothelial cell serum proteomics .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histology Staging Disease Histologically proven advance colorectal cancer ( CRC ) ; amenable curative surgery Of Note : In case single metastasis , histological cytological proof colorectal carcinoma obtain prior randomisation . Unidimensionally measurable disease ( &gt; = 1 cm spiral CT scan &gt; = 2 cm chest Xray ; liver ultrasound allow ) . Index lesions previously irradiate area . Serum carcinoembryonic antigen ( CEA ) may use parameter disease evaluation . In case previous radiotherapy , least one measurable lesion locate outside irradiated field . General Conditions Signed write informed consent Age 18 year World Health Organization ( WHO ) performance status 01 Adequate bone marrow function ( white blood cell count [ WBC ] &gt; 3.0 x 10^9/L , platelet &gt; 100 x 10^9/L , hemoglobin [ Hb ] &gt; 6 mmol/L ) Adequate hepatic function : total bilirubin &lt; 2 x upper normal limit , aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) &lt; 3 x upper normal limit ( case liver metastases &lt; 5 x upper normal limit ) Adequate renal function : serum creatinine &lt; 1.5 x upper normal limit Urinary protein excretion &lt; 0.5 gram/24h Expected adequacy followup Prior chemotherapy advance disease ; prior adjuvant chemotherapy allow provide last administration give &gt; 6 month prior randomisation , patient recover toxic event relate adjuvant chemotherapy , safety evaluation adjuvant chemotherapy present risk serious adverse event administration protocol treatment . Previous radiotherapy rectal cancer symptomatic treatment distant metastasis allow , provide least one measurable lesion locate outside irradiated field , irradiation complete least 4 week , patient recover side effect . Previous epidermal growth factor receptor ( EGFR ) target therapy Sensory neuropathy &gt; grade 1 Bleeding diathesis coagulation disorder need fulldose anticoagulation Major surgical procedure , open biopsy significant traumatic injury within 28 day prior start drug administration Anticipated major surgical procedure course study Serious nonhealing wound ulcer Any condition prevent intake absorption oral drug Significant cardiovascular disease ( unstable angina pectoris , recent myocardial infarction &lt; 12 month , uncontrolled hypertension , previous cerebrovascular disease ) Pregnancy lactation Patients ( males/females ) reproductive potential implementing adequate contraceptive measure Central nervous system metastasis ( asymptomatic patient screen require ) Serious active infection Other serious concomitant disease prevent safe administration study drug likely interfere study assessment Other malignancy past 5 year exception adequately treat carcinoma situ cervix squamous basal cell carcinoma skin Concomitant treatment : concomitant ( within 4 week randomisation ) administration experimental drug investigation ; concurrent treatment anticancer therapy ; fulldose anticoagulation Continuous use immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>cetuximab</keyword>
	<keyword>advanced colorectal cancer</keyword>
</DOC>